Диссертация (1154359), страница 38
Текст из файла (страница 38)
Kulkarni, Biosimilars: theneed, the challenge, thefuture: the FDA perspective. The American journalof gastroenterology. 2014. - №109(12). - p. 1856-1865.379.European Society of Hypertension identification and management ofthe hypertensive patient with elevated heat rate: statement of a EuropeanSociety of hypertension Consensus Meeting / P. Platini, A.
Benetos, G.Grassi [et al.] // J. Hypertens. – 2006. - Vol.24. - P. 603-610.380.Evans, W.E. Pharmacogenomics –drug disposition, drug targets, andside effects / W.E. Evans, H.L. McLeod // N Engl J Med. – 2003. – Vol.348 (6). – P. 538–549.381.Factors affecting patient compliance with antihyperlipidemic drugsin a lipid clinic / J.C.Y Sung, M.B. Nichol, F.
Venturini [et al.] // Am JManag Care. – 1998. – Vol. 4. – P. 1421—1430.382.Factors related to poor control of blood pressure with antihyperten-sive drug therapy / E. Jokisalo, H. Enlund, P. Halonen [et al.] // BloodPress. – 2003. – Vol. 12 (1). – P. 49–55.383.Fahey, T. Interventions used to improve control of blood pressure inpatients with hypertension / T. Fahey, K. Schroeder, S. Ebrahim // TheCochrane Database of Systematic Reviews. - The Cochrane Collaboration:John Wiley and Sons, Ltd., 2006. – N. 4.– P.
43.384.Feagan, B.G., et al., The challenge of indication extrapolation for in-fliximab biosimilars.Biologicals: journal of the International Associationof Biological Standardization, 2014. №42(4).- p. 177-183.385.Fiorino, G., et al., The use of biosimilars in immune-mediated dis-ease: A joint Italian Society of Rheumatology (SIR), Italian Society ofDermatology (SIDeMaST), and Italian Group ofInflammatory Bowel Disease (IG-IBD) position paper. Autoimmunity reviews. 2014. - №13(7).p.751-756.245386.Fletcher, A.P. Spontaneous adverse drug reaction reporting vs.
eventreporting vs. event monitoring: a comparison / A.P.Fletcher // J. Roy. Soc.Med. – 1991. – Vol. 84. – P. 341-344.387.From compliance to concordance: achieving shared goals in medi-cine taking // The Royal pharmaceutical society of Great Britain. WorkingParty report. - 1998.
Available at: www.medicinespartnership.org Accessed 05 Dec 2012.388.GaBI Online - Generics and Biosimilars Initiative. FDA advisersrecommend approval offilgrastim biosimilar. Mol, Belgium: Pro PharmaCommunications International 2015 [cited 2015 February]; Availablefrom:http://www.gabionline.net/Biosimilars/News/FDA-advisersrecommend- approval-of-filgrastim-biosimilar.389.Garrido, V. M. Health technology assessment – an introduction toobjectives, role of evidence and structures in Europe / V.M.
Garrido, R.Busse. – Copenhagen: WHO Regional Office for Europe, 2005.390.Gartlehner, G. Direct versus indirect comparisons: a summary of theevidence / G. Gartlehner, C.G. Moore // Int J Technol Assess Health Care.– 2008. – Vol. 24. – P. 170-177.391. Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype / El N.
Rouby, RM. Cooper-DeHoff // Current hypertension reports. – 2015. – Vol.17(9). – P.583. doi:10.1007/s11906-015-0583-8.392.Genetic polymorphisms associated with heart failure: A literature re-view / M. Guo, G. Guo, X. Ji // J Int Med Res. – 2016. – Vol. 44(1). – P.1529. doi:10.1177/0300060515604755.393.Genomics and Pharmacogenomics of Salt-sensitive Hypertension / I.Armando, V.A.
Villar, P.A. Jose // Curr Hypertens Rev. – 2015. – Vol.11(1). – P. 49-56.246394.Genetic Variations in Renin-Angiotensin-Aldosterone System(RAAS) Genes Could Contribute to High Altitude Pulmonary Edema / S.Srivastava // Review. J Pulm Respir Med. – 2015. – Vol.5 – P. 296.395.Genetic variants associated with angiotensin-converting enzyme in-hibitor-induced cough: a genome-wide association study in a Swedishpopulation / P.
Hallberg, M. Persson, T. Axelsson [et al.] // Pharmacogenomics. – 2017. - Vol. 18, No. 3. – P. 201-213.396.Gregory, P. Marchidon. Health System Perfomance in Canada: theGood, the Bad and the Ugly / P. Gregory Marchidon // Eurohealth Incorporating Euro Observer. – 2013. - Vol. 19, N. 2. - P.
32-35.397.Haig, K. One Hospital’s Journey Toward Patient Safety / K. Haig //Medscape Money & Medicine. – 2003. – Vol. 4(2).398.Hailey, D. Development of the International Network of Agenciesfor Health Technology Assesment / Hailey D. // Int J Technol AssessmentHealth Care. – 2009. – Vol. 25 (1). – P. 24-27.399.Hailey, D. Profile of an HTA program. Edmonton, The Alberta Her-itage Foundation for Medical Research Health Technology AssessmentUnit 2002–2003. (IP-16 Information Paper. February 2004). Availablefrom:http://www.inahta.org/upload/HTA_resources/AboutHTA_Resources_for_HTA.pdf.400.Havlir, D.V. Drug susceptibility in HIV infection after viral reboundin patients receiving indinavir-containing regimens /D.V.
Havlir //JAMA. – 2000. – Vol. 283(2). – P. 229–234.401.Health technology assessment in Canada / R.N. Battista, B. Cote,M.J. Hodge [at al.] // Int J Technol Assesment Health Care. – 2009. – Vol.25, N. 1. – P. 53-60.247402.Health technology assessment: a flexible approach? Experiences inLombardy / M. Amigoni [et al.] // Italian Journal of Public Health. 2005. - Vol. 2(2). - P. 9-14.403.Health Technology Assessment: Lessons Learned from Around theWorld – An Overview / J.C. O'Donnel, S.V.
Pharm, C.L. Pashos [at al.] //Value in Health. – 2009. – Vol. 12(2).404.Heart Disease and Stroke Statistics 2012 Update:A Report From theAmerican Heart Association Circulation 2012, 125 / V.L. Roger, A.S. Go,D.M. Lloyd-Jones [et al.] e2-e220:originally published online December15. – 2011: http://circ.ahajournals.org/content/125/1/e2.405.Hlavaty, T. and J. Letkovsky, Biosimilars in the therapy of inflam-matoryboweldiseases.Europeanjournalofgastroenterology&hepatology, 2014.
- №26(6). - p. 581-588.406.Hosie, J. Managing hypertension in general practice: can we do bet-ter? / J. Hosie, I.J. Wiklund // Human Hypertens. – 1995. – Vol. 9. – P. 1518.407.How to Teach Evidence-Based Medicine / D.L. Sackett,W.S. Rich-ardson, W. Rosenberg [at al.]. - 2nd ed. – New York: Churchill Livingstone, 2000.408.Hrybjartsson, A.The controlled clinical trial turns 100 years: Fib-iger's trial of serum treatment / A. Hrybjartsson, P.C. Guitzsche, C. Gluud// Brit. Med. J.
– 1998. – Vol. 317. – P.1243–1245.409.http://www.scardio.ru/.410.http://www.roszdravnadzor.ru/.411.http://www.zdrav.ru/news/1085731-qqn-16-m11-11-11-2016-v-2017-godu-klinicheskie-rekomendatsii-stanut-rukovodstvami248412.Hutton, J. Framework for describing and classifying decision-makingsystems using technology assessment to determine the reimbursement ofhealth technologies (fourth hurdle systems) / J. Hutton // Int J Technol Assessment Health Care. – 2012. – Vol. 21 (1). – P. 10 – 18.413.Hypertensive left ventricular hypertrophy risk: beyond adaptive hy-pertrophy. Frohlich E.D., Gonzales A.
Journal of hypertension. – 2011. Vol: 29 (1). P. 17-26. DOI: 10.1097/HJH.0b013e328340d787.414.Identifying and Valuing Outcomes / M.R. Gold, D.L. Patrick, G.W.Torrance [et al.] // CostEffectiveness in Health and Medicine / M.R. Gold,J.E. Siegel, L.B. Russell L.B.
eds. - New York: Oxford University Press,1996. - P. 82–134.415.Immunological principles of adverse drug reactions: the initiationand propagation of immune responses elicited by drug treatment / D.J.Naisbitt , S.F. Gordon , M. Pirmohamed [at al.] // Drug. Saf. – 2000.
–Vol. 23(6). – P. 483-507.416.Impact of adherence and highly active antiretroviral therapy on sur-vival in HIV-infected patients / P. G. de Olalla, H. Knobel, A. Carmova[et al.] // J. Acquir. Immune Defic. Syndr. – 2002. – Vol. 30. – P.
105-110.417.Impact of the β-1 adrenergic receptor polymorphism on tolerabilityand efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapyin heart failure (ABBA) study / H-Y Lee, W-J Chung, H-K Jeon [et al.] //The Korean Journal of Internal Medicine. – 2016. – Vol.31(2). – P. 277287. doi:10.3904/kjim.2015.043.418.Impact of medication therapy discontinuation on mortality after my-ocardial infarction / P. Ho, J.
Spertus, F. Masoudi [et al.] // Arch. Intern.Med. – 2006. – Vol. 166. – P. 1842–1847.249419.Impact of osteoporosis treatment adherence on fracture rates in NorthAmerica and Europe / E.S. Siris, P.L. Selby, K.G. Saag [et al.] // Am. J.Med. - 2009. - Vol. 122. – P. 3-13.420.Impact of I/D polymorphism of ACE gene on risk of developmentand course of chronic obstructive pulmonary disease / R Mlak, I HomaMlak, T Powrózek [et al.] // Archives of Medical Science : AMS. - 2016.– Vol.12(2). – P. 279-287.
doi:10.5114/aoms.2015.50757.421.Improving the quality of reporting of randomised controlled trials /C. Begg, M. Cho, S. Eastwood [et al.]// JAMA. – 1996. – Vol. 276. – P.637–639.422.Incidence of adverse drug events and potential adverse drug events.Implications for prevention / D.W. Bates, D.J. Cullen, N. Laird [et al.] //JAMA. – 1995. – Vol. 274. – P. 29-34.423.Inmam, W.H.W. Monitoring for drug safety / W.H.W.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
